Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug

• Main Authors: Alan Faraj (Author), Tom Knudsen (Author), Shraddha Desai (Author), Linda Neuman (Author), Grant E. Blouse (Author), Ulrika S. H. Simonsson (Author)
• Format: Book
• Published: Wiley, 2022-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Marzeptacog alfa (activated) (MarzAA) is an activated recombinant human FVII (rFVIIa) variant developed as subcutaneous (s.c.) administration for the treatment or prevention of bleeding episodes in patients with hemophilia A (HA) or hemophilia B (HB) with inhibitors and other rare bleeding...